DH Enchantment Inc. (ENMI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DH Enchantment Inc. (ENMI) trades at $0.00 with AI Score 42/100 (Grade C). DH Enchantment Inc. distributes COVID-19 rapid antigen test kits in Hong Kong. Market cap: $383,131, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for ENMI: ENMI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ENMI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ENMI: the 1 perspectives are evenly split.
How is this calculated? →DH Enchantment Inc. (ENMI) Healthcare & Pipeline Overview
DH Enchantment Inc. focuses on the distribution of COVID-19 rapid antigen test kits in Hong Kong, serving personal hygiene product distributors. Formerly Energy Management International, the company rebranded in 2021. With a negative profit margin and OTC listing, ENMI faces significant challenges in a competitive healthcare distribution market.
What Is the Investment Thesis for ENMI?
Investing in DH Enchantment Inc. presents a high-risk, high-reward scenario. The company's focus on COVID-19 rapid antigen test kit distribution in Hong Kong offers potential upside, but its financial performance raises concerns. With a negative profit margin of -71.1% and a small market capitalization, the company's financial stability is questionable. The company's beta of 2.54 indicates high volatility. The success of ENMI hinges on its ability to secure and maintain distribution contracts, manage costs effectively, and adapt to evolving market demands for COVID-19 testing. Investors should closely monitor the company's financial performance and competitive positioning before considering an investment.
Based on FMP financials and quantitative analysis
ENMI Key Highlights
- Market Cap of 383K indicates a micro-cap company with limited resources.
- P/E Ratio of -0.72 reflects negative earnings, suggesting the company is currently unprofitable.
- Profit Margin of -71.1% highlights significant challenges in achieving profitability.
- Gross Margin of 32.1% indicates some efficiency in production and distribution, but is offset by high operating costs.
- Beta of 2.54 suggests the stock is highly volatile compared to the overall market.
Who Are ENMI's Competitors?
ENMI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CWB State Street SPDR Bloomberg Convertible Securities ETF | $105.34 | +0.92% | $4.62B | 47 |
| TDV ProShares - S&P Technology Dividend Aristocrats ETF | $100.89 | +1.33% | $293.21M | 47 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $46.97 | +0.26% | $363.40M | 47 |
| KSTR KraneShares SSE STAR Market 50 Index ETF | $28.75 | +2.00% | $67.07M | 47 |
| FTQGX Fidelity Focused Stock Fund | $48.04 | -2.26% | $5.41B | 44 |
| SHAPX ClearBridge Appreciation A | $36.64 | +0.80% | $9.79B | 44 |
| FGFRX Federated Hermes International Leaders Fund Class R | $47.03 | +1.34% | $1.53B | 44 |
| SBYEX BNY Mellon Diversified Emerging Markets Fund | $23.10 | -0.04% | $48.80M | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ENMI's Key Strengths?
- Established presence in the Hong Kong market.
- Focus on COVID-19 rapid antigen test kit distribution.
- Existing relationships with personal hygiene product distributors.
What Are ENMI's Weaknesses?
- Negative profit margin.
- Small market capitalization.
- Limited product diversification.
- Dependence on a single market (Hong Kong).
What Could Drive ENMI Stock Higher?
- Potential new distribution agreements with healthcare providers.
- Fluctuations in COVID-19 infection rates impacting demand for test kits.
- Potential expansion into new geographic markets.
What Are the Key Risks for ENMI?
- Financial-distress signal — its Altman Z-Score of -0.95 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition in the medical distribution industry.
- Evolving regulatory requirements impacting product approvals.
- Dependence on a single product category (COVID-19 rapid antigen test kits).
- Supply chain disruptions affecting product availability.
- Negative profit margin and financial instability.
What Are the Growth Opportunities for ENMI?
- Expansion into New Markets: DH Enchantment Inc. could explore opportunities to expand its distribution network beyond Hong Kong. By targeting neighboring regions or countries with similar healthcare needs, the company could diversify its revenue streams and reduce its reliance on a single market. This expansion could involve establishing partnerships with local distributors or setting up its own distribution channels. The timeline for this expansion would depend on regulatory approvals and market entry strategies, potentially within the next 2-3 years.
- Diversification of Product Portfolio: The company could diversify its product portfolio to include other medical diagnostic products or healthcare-related items. By offering a broader range of products, DH Enchantment Inc. could attract a wider customer base and increase its revenue potential. This diversification could involve partnering with other manufacturers or developing its own branded products. The timeline for this diversification could be within the next 1-2 years.
- Strategic Partnerships: DH Enchantment Inc. could form strategic partnerships with healthcare providers, hospitals, or clinics to secure distribution contracts and increase its market reach. By collaborating with established healthcare institutions, the company could gain access to a larger customer base and enhance its reputation. These partnerships could involve exclusive distribution agreements or joint marketing initiatives. The timeline for establishing these partnerships could be within the next year.
- Online Sales Platform: Developing an online sales platform could enable DH Enchantment Inc. to reach a wider customer base and streamline its distribution process. By offering its products directly to consumers through an e-commerce website, the company could reduce its reliance on traditional distribution channels and increase its profit margins. This online platform could also provide valuable data on customer preferences and market trends. The timeline for developing this online platform could be within the next 6-12 months.
- Government Contracts: Securing government contracts to supply COVID-19 rapid antigen test kits could provide DH Enchantment Inc. with a stable revenue stream and enhance its credibility. By participating in government tenders and bidding processes, the company could gain access to large-scale procurement opportunities. These contracts could involve supplying test kits to schools, hospitals, or other public institutions. The timeline for securing these contracts would depend on the government's procurement schedules and the company's ability to meet the required specifications.
What Opportunities Does ENMI Have?
- Expansion into new markets.
- Diversification of product portfolio.
- Strategic partnerships with healthcare providers.
- Development of an online sales platform.
- Securing government contracts.
What Threats Does ENMI Face?
- Intense competition in the medical distribution industry.
- Evolving regulatory requirements.
- Fluctuating demand for COVID-19 testing products.
- Supply chain disruptions.
- Economic downturn in Hong Kong.
What Are ENMI's Competitive Advantages?
- Established distribution network in Hong Kong.
- Existing relationships with personal hygiene product distributors.
- Focus on a specific niche market (COVID-19 rapid antigen test kits).
What Does ENMI Do?
DH Enchantment Inc., established in 2004 and based in Kowloon, Hong Kong, operates in the healthcare sector as a distributor of COVID-19 rapid antigen test kits. Through its subsidiary, Ho Shun Yi Limited, the company focuses on supplying these test kits to personal hygiene product distributors within Hong Kong. Originally incorporated as Energy Management International, Inc., the company underwent a name change in August 2021 to DH Enchantment Inc., signaling a shift in its business focus. The company's current operations are centered around the distribution of medical diagnostic products, specifically catering to the increased demand for COVID-19 testing solutions. With a small team of one employee, DH Enchantment Inc. navigates a competitive market landscape, striving to maintain its position as a key supplier of essential healthcare products in the region. The company's ability to adapt to changing market dynamics and regulatory requirements will be critical to its long-term success.
What Products and Services Does ENMI Offer?
- Distributes COVID-19 rapid antigen test kits.
- Operates through its subsidiary, Ho Shun Yi Limited.
- Serves personal hygiene product distributors in Hong Kong.
- Focuses on supplying medical diagnostic products.
- Caters to the demand for COVID-19 testing solutions.
How Does ENMI Make Money?
- Procures COVID-19 rapid antigen test kits from manufacturers.
- Distributes these test kits to personal hygiene product distributors.
- Generates revenue through the sale of test kits.
- Focuses on serving the Hong Kong market.
What Industry Does ENMI Operate In?
DH Enchantment Inc. operates within the medical distribution industry, specifically focusing on COVID-19 rapid antigen test kits. The industry is characterized by intense competition, evolving regulatory requirements, and fluctuating demand based on public health conditions. The company's success depends on its ability to secure distribution contracts, manage supply chains effectively, and adapt to changing market dynamics. Competitors include companies like CBDG, CSTF, DPAT, KJFI, and LVTTF, all vying for market share in the healthcare distribution sector. The demand for COVID-19 testing products is subject to changes in infection rates and government policies, creating both opportunities and challenges for DH Enchantment Inc.
Who Are ENMI's Key Customers?
- Personal hygiene product distributors in Hong Kong.
- Healthcare providers.
- Hospitals and clinics.
ROE 17%Key Financial Metrics
Return on equity for DH Enchantment Inc. stands at 17.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -30.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -187.8%, the inverse of the P/E and a quick read on earnings relative to price.
How DH Enchantment Inc. Is Valued
DH Enchantment Inc. carries a market capitalization of 383K, placing it in the micro-cap category. Relative to its peer group, ENMI's quantitative score of 42/100 is roughly in line with the peer average of 46/100.
F-Score 3/9Financial Health
DH Enchantment Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.95 places it in the distress zone, a signal of elevated financial risk.
ENMI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Established presence in the Hong Kong market.
- Focus on COVID-19 rapid antigen test kit distribution.
- Existing relationships with personal hygiene product distributors.
- Upcoming: Potential new distribution agreements with healthcare providers.
Bear Case
- Negative profit margin.
- Small market capitalization.
- Limited product diversification.
- Dependence on a single market (Hong Kong).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ENMI Latest News
No recent news available for ENMI.
ENMI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ENMI.
Price Targets
Wall Street price target analysis for ENMI.
ENMI MoonshotScore
What does this score mean?
The MoonshotScore rates ENMI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Cheuk Yin Cheung
Unknown
Information on Cheuk Yin Cheung's background is not available. Details regarding their career history, education, and previous roles are unknown. Further research is needed to gather more information about their professional experience and qualifications.
Track Record: Information on Cheuk Yin Cheung's track record is not available. Specific achievements, strategic decisions, and company milestones under their leadership are unknown. Further research is needed to assess their performance and impact on the company.
ENMI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier often face challenges related to financial reporting, regulatory compliance, and corporate governance. These securities may lack readily available information and are subject to higher levels of risk and volatility compared to those listed on higher tiers or major exchanges like NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before considering investments in OTC Other securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other listing.
- High volatility and price fluctuations.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Limited liquidity and difficulty in trading shares.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC securities.
- Consult with a financial advisor.
- Monitor news and developments related to the company.
- Company has been in operation since 2004.
- Company has a subsidiary, Ho Shun Yi Limited.
- Company distributes COVID-19 rapid antigen test kits.
DH Enchantment Inc. Healthcare Stock: Key Questions Answered
What does DH Enchantment Inc. do?
DH Enchantment Inc. operates as a distributor of COVID-19 rapid antigen test kits in Hong Kong, primarily serving personal hygiene product distributors. Through its subsidiary, Ho Shun Yi Limited, the company focuses on supplying these test kits to meet the demand for rapid testing solutions. The company's business model revolves around procuring test kits from manufacturers and distributing them to its network of distributors, generating revenue through sales. DH Enchantment Inc. aims to provide accessible and reliable testing solutions to support public health efforts in Hong Kong.
What do analysts say about ENMI stock?
As of 2026-03-17, there is no available analyst coverage for DH Enchantment Inc. due to its OTC listing and small market capitalization. Key valuation metrics such as price targets and ratings are not available. Investors should conduct their own independent research and due diligence before considering an investment in ENMI. Factors to consider include the company's financial performance, competitive positioning, and growth prospects. The lack of analyst coverage increases the risk associated with investing in this stock.
What are the main risks for ENMI?
Investing in DH Enchantment Inc. involves several risks, including its negative profit margin, small market capitalization, and dependence on a single product category (COVID-19 rapid antigen test kits). The company operates in a competitive industry with evolving regulatory requirements and fluctuating demand. Supply chain disruptions could also impact product availability. Additionally, the company's OTC listing and limited financial disclosure increase the risk of investing in this stock. Investors should carefully consider these risks before making an investment decision.
What are the key factors to evaluate for ENMI?
DH Enchantment Inc. (ENMI) holds an AI score of 42/100 (low). Not financial advice.
How frequently does ENMI data refresh on this page?
ENMI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ENMI's recent stock price performance?
DH Enchantment Inc. (ENMI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the Hong Kong market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ENMI overvalued or undervalued right now?
Valuing DH Enchantment Inc. (ENMI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ENMI?
Before investing in DH Enchantment Inc. (ENMI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing increases the risk of investing in this stock.
- Lack of analyst coverage.